News

NEW YORK (August 4, 2025) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a case study demonstrating the clinical use of its FDA-cleared hemostatic medical device, TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2025 Military Health System […]

Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply company NEW YORK (June 16, 2025) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy

Innovative hemostatic gel now available to EMS agencies, first responders, emergency departments, and trauma centers across the U.S. NEW YORK (January 13, 2025) – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the U.S. commercial launch of TRAUMAGEL®, a revolutionary plant-based hemostatic gel that controls bleeding in seconds when applied

License Agreement Expands Zomedica’s Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with

NEW YORK, Sept. 16, 2024 — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has been selected to exhibit TRAUMAGEL®, a first-of-its-kind hemostatic medical device with FDA 510(k) clearance for temporary external use for controlling moderate to severe bleeding, at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest

Hemostatic gel designed to control moderate to severe bleeding in seconds and save lives NEW YORK August 15, 2024 – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for TRAUMAGEL® (“TRAUMAGEL”) for temporary external use for controlling

Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9, 2024 — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced the successful completion of the first phase of a preclinical study conducted with the Walter Reed Army Institute

Partnership provides VerticalVet’s 1,800 veterinary members with access to market-leading hemostatic agent NEW YORK (June 11, 2024) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a Preferred Partnership Agreement with VerticalVet, LLC to provide the organization’s Group Purchasing Organization (GPO) members with access

Original news piece from Fast Company: https://www.fastcompany.com/91114595/stopping-bleeding-instantly Cresilon’s game-changing gel technology will soon be saving lives in emergency rooms Severe blood loss, whether the result of an accident or a complication during surgery, can result in death within minutes. An easy-to-use technology that can instantly stop severe bleeding would have the potential to save countless